![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sofosbuvir Compassionate Use Program for Patients with Severe Recurrent Hepatitis C Including Fibrosing Cholestatic Hepatitis Following Liver Transplantation
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Xavier Forns1, Martin Prieto2, Michael Charlton3, John G. McHutchison4,
William T. Symonds4, Diana Brainard4, Jill Denning4, Theo Brandt-Sarif4,
Paul Chang4, Valerie Kivett4, Robert J. Fontana5, Thomas F. Baumert6,
Audrey Coilly7, Lluis Castells8, François Habersetzer6
1Liver Unit, IDIBAPS, CIBEREHD, Hospital Clinic, Barcelona, Spain; 2Hepatology Unit, CIBEREHD, Hospital Universitari i Politecnic La Fe, Valencia, Spain; 3Mayo Clinic, Rochester, MN, USA; 4Gilead Sciences, Foster City, CA, USA; 5University of Michigan, Ann Arbor, MI, USA; 6Hopitaux Universitaires de Strasbourg, Inserm U 1110, Strasbourg, France; 7Centre Hepato-Bilaire, Hopital
Paul Brousse, Inserm UMR-S785, Villejuif, France; 8Liver Unit-Internal Medicine Department, CIBEREHD, Hospital Universitari Vall Hebron, Barcelona
![EASL1.gif](../images/041414/041414-14/EASL1.gif)
![EASL2.gif](../images/041414/041414-14/EASL2.gif)
![EASL3.gif](../images/041414/041414-14/EASL3.gif)
![EASL4.gif](../images/041414/041414-14/EASL4.gif)
![EASL5.gif](../images/041414/041414-14/EASL5.gif)
![EASL6.gif](../images/041414/041414-14/EASL6.gif)
![EASL7.gif](../images/041414/041414-14/EASL7.gif)
![EASL8.gif](../images/041414/041414-14/EASL8.gif)
![EASL9.gif](../images/041414/041414-14/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|